FOR UK HEALTHCARE PROFESSIONALS ONLY

Cost Saving

For more information about Sevodyne, please see the prescribing information.

By prescribing Sevodyne® by brand you could save 69% on your
current buprenorphine 7-day transdermal patches prescribing costs.1**

By prescribing Sevodyne by brand, the average savings for an ICS could be £467,000 per year,²* providing the NHS with a total potential annual prescribing cost saving of approximately £19.6 million.²*

Sevodyne Cost Calculator

To find out how much you could save by prescribing Sevodyne, please follow the instructions on the Sevodyne calculator:

View the cost calculator

Sevodyne is part of the cost-saving prolonged-release product range from Aspire Pharma.

  • 69% saving on UK Drug Tariffs price for buprenorphine transdermal patches1**
  • Available from mainline wholesalers
  • Price guaranteed***
Product UK Drug Tariffs price¹ Sevodyne price NHS Saving when Sevodyne is Prescribed
Buprenorphine transdermal patch 5 microgram/hr x 4 £17.60 £5.53 £12.07
Buprenorphine transdermal patch 10 microgram/hr x 4 £31.55 £9.93 £21.62
Buprenorphine transdermal patch 15 microgram/hr x 4 £49.15 £15.48 £33.67
Buprenorphine transdermal patch 20 microgram/hr x 4 £57.46 £18.09 £39.37
*Savings based on market data in reference 2. Insypher Data, captures the spend of comparable strengths of Sevodyne (Buprenorphine transdermal patches, 5,10,15, 20mcg) within a given data period (3 months) and times this figure by 4 to assume an annual cost of generic buprenorphine patches based on UK drug tariff prices. The total number of prescriptions was then calculated based on the cost of Sevodyne. The average ICS cost saving is based on annualised savings divided by 42 ICS/ICB’
 **Based on 69% saving on the cost of buprenorphine transdermal patches in the UK Drug Tariffs. ***No change in price subject to no material change to the products of the UK Drug Tariffs until the 2024 PPRS review.
References: 1) Novemeber 2022 UK Drug Tariffs. 2 Insypher Data :Date Range: May-22 -Jul-2210100831045 v 8.0 October 2022)
Adverse events should be reported. Reporting forms and information can be found at:

Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148.www.mhra.gov.uk/yellowcard

SEV1010311C1_NOV2022

More products available
in this range:
Click to view their
individual websites